Finance

Lists
Why is 326030 down 3.48%?
Dive Deeper
326030:KRX
SK Biopharmaceuticals Co Ltd
₩85,900.00
-3.48%
(-3,100.00) 1D
Nov 18, 3:30:15 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 326030...
Open
₩87,900
High
₩89,200
Low
₩85,000
Mkt. cap
6.73T
Avg. vol.
186.53K
Volume
226.62K
P/E ratio
17.65
52-wk high
₩144,100
52-wk low
₩67,800
EPS
₩4,867
Shares outstanding
78.31M
No. of employees
246
Open
₩87,900
High
₩89,200
Low
₩85,000
Mkt. cap
6.73T
Avg. vol.
186.53K
Volume
226.62K
P/E ratio
17.65
52-wk high
₩144,100
52-wk low
₩67,800
EPS
₩4,867
Shares outstanding
78.31M
No. of employees
246
News stories
From web sources and news partners
ING Sprinters
ING Sprinters
·
12 hours ago
De AEX Index breekt steun
ZeelandNet, startpagina van Zeeland
ZeelandNet, startpagina van Zeeland
·
13 hours ago
AEX-index lager, chipbedrijven dalen in aanloop cijfers Nvidia
About SK Biopharmaceuticals Co Ltd
CEO-
Employees246
Founded1993
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteskbp.com
Previous reportsAll values in KRW
Loading Previous Earnings...
Revenue
Net income
All values in KRW
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
191.73B
194.36B
227.89B
247.37B
Cost of goods sold
7.55B
14.95B
14.33B
15.02B
Cost of revenue
7.55B
14.95B
14.33B
15.02B
Research and development expenses
40.93B
51.85B
47.59B
49.66B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
68.98B
77.42B
71.09B
81.28B
Operating expense
114.07B
133.13B
123.79B
135.29B
Total operating expenses
121.62B
148.08B
138.12B
150.30B
Operating income
70.11B
46.28B
89.77B
97.06B
Other non operating income
-8.46B
-7.51B
-5.78B
-5.76B
EBT including unusual items
62.11B
33.76B
99.98B
93.36B
EBT excluding unusual items
61.27B
36.66B
89.89B
89.81B
Income tax expense
-9.26B
-98.98B
-2.76B
8.30B
Effective tax rate
-14.90%
-293.19%
-2.76%
8.88%
Other operating expenses
1.37B
1.11B
2.22B
1.42B
Net income
74.14B
136.59B
105.16B
85.06B
Net profit margin
38.67%
70.28%
46.15%
34.39%
Earnings per share
-
-
-
-
Interest and investment income
1.88B
1.72B
1.68B
2.37B
Interest expense
-1.70B
-1.32B
-1.30B
-1.26B
Net interest expenses
179.24M
397.10M
380.91M
1.11B
Depreciation and amortization charges
2.23B
2.18B
2.19B
2.17B
EBITDA
74.11B
50.23B
93.70B
101.08B
Gain or loss from assets sale
10.55M
176.00M
-
1.00K
Upcoming events
AI content may include mistakes. Learn more
Google apps